Summer 2026

Quality Data Analyst Intern

Posted on 5/16/2026

Tandem Diabetes Care

Tandem Diabetes Care

1,001-5,000 employees

Develops subcutaneous insulin pumps and software

Compensation Overview

$30 - $41/hr

No H1B Sponsorship

San Diego, CA, USA

Hybrid

Hybrid role; on-site required in San Diego, CA.

Category
Data & Analytics (1)
Required Skills
Power BI
Minitab
Python
SQL
ETL
Tableau
Data Governance
Databricks
Data Analysis
Requirements
  • Experienced with MS Office (Word, Excel, Outlook, PowerPoint) and effectively use MiniTab or other applicable statistical software.
  • Possess analytical skills and the ability to work independently.
  • Good organizational skills with the ability to prioritize workload.
  • Able to effectively convey information related to work product in one on one conversation or in a group.
  • Able to work effectively in a team environment.
  • Strong analytical and problem-solving skills. Able to present analysis to various stakeholders.
  • Technical knowledge of database and reporting tools.
  • Experience creating interactive dashboards using tools like Power BI or Tableau.
  • Experience with extracting, transforming, and loading data from various data sources into a single data report.
  • Coding skills in languages such as SQL, Python, or equivalent. Experience with Databricks is a plus.
  • Strong knowledge and application of principles outlined in Good Manufacturing Practices (GMP).
  • Capable of producing, interpreting and analyzing results using statistical methodology, including control charts.
  • Able to assert own ideas and persuade others through effectively consolidating, evaluating, and presenting relevant information.
  • Experience working with large datasets and performing data analysis using statistical methods.
  • Continuously monitor and initiate improvement opportunities with data quality and integrity.
  • Adept at seeing change as an opportunity to improve business performance.
  • Excellent verbal and written communication skills and flexibility to function in a fast paced and innovative environment.
  • Knowledge of data governance and data security best practices.
  • Able to alter behavior and opinions in light of new information.
  • Knowledge of problem solving methodologies: 5 why’s analysis, Cause and Effect diagrams, etc.
Responsibilities
  • Partners with Quality Engineering and cross-functional team members to conduct data analysis reports to support post market risk management activities, product monitoring and quality investigations.
  • Define and implement Power BI dashboards, reports and analyses associated with post market surveillance data and metrics that can make data and insights more easily available to non-technical stakeholders.
  • Works with Business Intelligence and IT team members to develop and implement IT solutions to support the company’s analytics needs.
  • Collaborates with others in Operations, R&D Quality, Customer Technical Support, Clinical Evaluation, Failure Investigation, Risk Management, Global Post Market Surveillance and other internal groups.
  • Quality Data Analyst Interns are also responsible for: Collaborates with stakeholders across Tandem’s business units to provide scalable reporting and analytics solutions associated with post market surveillance data.
  • Creates interactive and automated Power BI dashboards and data reports.
  • Collaborate with data scientists, data engineers, and other IT professionals to deliver comprehensive data solutions and reports to increase data analysis efficiencies.
  • Provides ad-hoc analyses and written reports as needed.
  • Participates in problem definition and user needs gathering with project teams and business process owners.
  • Facilitates and participates on cross-functional process improvement teams to drive operational quality excellence and cost savings initiatives.
  • Trains cross-functional stakeholders on data use and access.
  • Enables non-technical stakeholders to quickly answer key questions and make better and faster decisions through easy access to data and analytics tools.
  • Assists in incorporating data from multiple sources including product, ERP, CRM, and other business applications to present consolidated views of post market surveillance data.
  • Confirms completion of required training plan before assuming job responsibilities.
  • Ensures compliance with company policies, including Privacy/HIPAA, and other legal and regulatory requirements.
  • Other responsibilities as assigned.
  • Performs other duties as assigned.
  • Minimum experience items relocated into responsibilities:
  • Assists in collecting, cleaning and validating data from multiple sources
  • Support the development and maintenance of dashboards, reports, and visualizations
  • Perform basic data analysis to identify trends, patterns and anomalies
  • Help document business definitions, metrics and reporting logic
  • Support enhancements to existing dashboards and reports
  • Assist with testing and validation of reports to ensure data accuracy and consistency
  • Help maintain data quality and reporting standards
  • Work with cross functional teams to understand business requirements
  • Support ad-hoc reporting and analysis requests
  • Assist in preparing presentation materials and summaries for process stakeholders
  • Help document process workflows
  • Support continuous improvement initiatives related to analytics and reporting efficiency
  • Assist in defining and validating key performance indicators
  • Perform QA checks to validate data accuracy
Desired Qualifications
  • Completion of Junior year in Science or Engineering or a related field, preferred
  • Intern experience in related environment, preferred

Tandem Diabetes Care designs and sells insulin pumps and related software for people with diabetes. Its flagship product is the t:slim X2 insulin pump, a subcutaneous device that delivers insulin and can work with other diabetes management devices through interoperable technology. A key feature is Basal-IQ, which uses continuous glucose monitoring data to predict low blood sugar and pause insulin delivery to prevent hypoglycemia. The company generates revenue from selling pumps and accessories like infusion sets and cartridges, as well as software updates and subscriptions for advanced management features, creating recurring income. Tandem differentiates itself with interoperable hardware and software that aim to simplify diabetes care and integrate with other devices, not just sell a single pump. Its goal is to improve diabetes management and quality of life by providing user-friendly, connected insulin delivery and management solutions for patients aged six and older.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

2006

Simplify Jobs

Simplify's Take

What believers are saying

  • Pharmacy distribution expands access and supports recurring consumable revenue.
  • International expansion in Switzerland, Austria, and the UK lifts pricing and volume.
  • Record 2025 sales above $1.015 billion show scale before new launches.

What critics are saying

  • Abbott CGM ecosystem integration weakens Tandem's platform differentiation.
  • Pharmacy transition creates a $70 million to $80 million 2026 revenue headwind.
  • Infusion set supply constraints limit pump shipments and recurring accessory sales.

What makes Tandem Diabetes Care unique

  • t:slim X2 and Mobi use Control-IQ+ predictive automation with CGM integration.
  • Mobi adds smartphone compatibility and a tubeless form factor by 2027.
  • FDA pregnancy clearance strengthens Tandem's clinical positioning in type 1 diabetes.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Tandem Diabetes Care who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

Remote Work Options

Hybrid Work Options

Employee Stock Purchase Plan

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Stock Titan
Mar 27th, 2026
Board asks shareholders to approve 3.26m-share increase; TNDM files proxy (TNDM).

Board asks shareholders to approve 3.26m-share increase; TNDM files proxy (TNDM). Filing Impact Filing Sentiment Rhea-AI Filing Summary. Tandem Diabetes Care is holding its 2026 Annual Meeting virtually on May 20, 2026 to vote on seven proposals, including election of nine directors, say-on-pay, an increase of 3,260,000 shares to the 2023 Long-Term Incentive Plan, certificate of incorporation amendments, and ratification of Ernst & Young LLP as auditor. The Record Date shows 68,504,233 shares outstanding as of March 23, 2026. The company reports 2025 business highlights including $1.015 billion in worldwide sales, over 126,000 pump shipments, and several product and regulatory milestones. Insights. Proxy seeks shareholder approval for governance and charter amendments alongside routine meeting items. The proxy presents six board-recommended proposals plus general meeting mechanics for the May 20, 2026 virtual meeting and discloses 68,504,233 shares outstanding as of March 23, 2026. Two charter amendments are proposed: a Section 141(k) removal amendment and an officer exculpation amendment tied to recent DGCL changes. Key dependencies include supermajority vote thresholds: the Section 141(k) and Officer Exculpation Amendments each require 66 2/3% approval. Subsequent filings will report vote results in a Form 8-K within four business days after the meeting. Board requests a 3,260,000-share increase to the 2023 equity plan and summarizes 2025 pay outcomes. The board proposes adding 3,260,000 shares to the 2023 Long-Term Incentive Plan and discloses current availability and activity metrics: 729,748 shares available as of March 16, 2026, a 2025 burn rate of 3.1%, and historical grants shown through March 16, 2026. The plan retains features such as minimum 12-month vesting, anti-repricing, clawback provisions, and director grant caps. Outcomes will hinge on shareholder approval; if not approved, the company states it may exhaust current reserves and be unable to grant customary awards thereafter. 03/27/2026 - 04:07 PM | / | / | / | / | / | / | / | / | / | Value of initial fixed $100 investment based on: | / | / | / | / | | Year | Summary Compensation Table Total for PEO(1) | / | CAP to PEO(1)(3) | / | Average Summary Compensation Table Total for Non-PEO NEOs(2) | / | Average CAP to Non-PEO NEOs(2)(3) | / | Total Shareholder Return(4) | / | Peer Group Total Shareholder Return TSR(4) | / | Net Income (loss) ($ in millions)(5) | / | Sales ($ in millions)(6) | | 2025 | $ | 6,858,503 | / | / | $ | 2,919,024 | / | / | $ | 1,970,448 | / | / | $ | 1,579,586 | / | / | $ | 22.97 | / | / | $ | 99.39 | / | / | $ | (204.7) | / | / | $ | 1,014.7 | / | | 2024 | $ | 8,526,238 | / | / | $ | 6,793,928 | / | / | $ | 1,945,074 | / | / | $ | 1,752,852 | / | / | $ | 60.43 | / | / | $ | 105.42 | / | / | $ | (96.0) | / | / | $ | 940.2 | / | | 2023 | $ | 4,651,603 | / | / | $ | 1,510,100 | / | / | $ | 1,497,536 | / | / | $ | 1,086,227 | / | / | $ | 49.62 | / | / | $ | 106.34 | / | / | $ | (222.6) | / | / | $ | 747.7 | / | | 2022 | $ | 6,378,515 | / | / | $ | (8,343,937) | / | / | $ | 1,746,125 | / | / | $ | (3,175,063) | / | / | $ | 75.41 | / | / | $ | 99.81 | / | / | $ | (94.6) | / | / | $ | 801.2 | / | | 2021 | $ | 5,739,882 | / | / | $ | 16,412,581 | / | / | $ | 1,616,639 | / | / | $ | 5,058,736 | / | / | $ | 252.51 | / | / | $ | 125.43 | / | / | $ | 15.6 | / | / | $ | 702.8 | / | 2) The non-PEO NEOs, for each year reported were as follows: - 2025: Elizabeth A. Gasser, Shannon Hansen, Mark D. Novara and Leigh A. Vosseller - 2024: Elizabeth A. Gasser, Jean-Claude Kyrillos, Susan M. Morrison, Mark D. Novara and Leigh A. Vosseller - 2023: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison, Mark D. Novara and Leigh A. Vosseller - 2022: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison and Leigh A. Vosseller - 2021: David B. Berger, Elizabeth A. Gasser, Brian B. Hansen, Susan M. Morrison and Leigh A. Vosseller | Year | Executive(s) | / | Summary Compensation Table Total | / | Deduct: Stock Awards Granted in Year | / | Add: Year-End Fair Value of Unvested Equity Awards Granted in Year* | / | Add: Change in Year-End Fair Value of Unvested Equity Awards Granted in Prior Years | / | Add: Change in Year-End Fair Value of Equity Awards Granted in Prior Years Which Vested in Year | / | CAP | / | / | / | / | | 2025 | PEO | / | $ | 6,858,503 | / | / | $ | (5,367,796) | / | / | $ | 5,240,252 | / | / | $ | (2,611,510) | / | / | $ | (1,200,425) | / | / | $ | 2,919,024 | / | / | / | / | / | | Non-PEO NEOs | / | $ | 1,970,448 | / | / | $ | (1,226,792) | / | / | $ | 1,197,646 | / | / | $ | (166,600) | / | / | $ | (195,116) | / | / | $ | 1,579,586 | / | / | / | / | / | | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | * The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. 6) As required by Item 402(v) of Regulation S-K, we have determined that Sales is the Company-Selected Measure. * Annual sales for 2024, 2023 and 2022 include the effect of net sales recognized (deferred) of $30.2 million, ($25.1) million and ($3.5) million, respectively. This related to the accounting treatment associated with our Tandem Choice Program offering, which began in September 2022 and ended December 31, 2024, to provide a pathway to eligible t:slim X2 customers to ownership of our newest hardware platform, Tandem Mobi, for a fee when available. There was no comparative adjustment to pump sales in 2025. | Most Important Performance Measures Used to Link CAP to Company Performance: | | Sales | | Gross Margin | | Adjusted EBITDA Margin* | | New Product Launch Timing | | Customer Satisfaction | | / | We have not granted stock options, stock appreciation rights, or similar instruments with option-like features since 2022 and have no policies or practices to disclose pursuant to Item 402(x)(1) of Regulation S-K. Faq. What is Tandem Diabetes Care (TNDM) voting on at the 2026 annual meeting? The company asks shareholders to elect nine directors and vote on six additional items. These include say-on-pay, a 3,260,000 -share increase to the 2023 equity plan, two charter amendments, and ratification of Ernst & Young LLP as auditor. When and how will TNDM shareholders vote at the 2026 Annual Meeting? The virtual meeting is scheduled for May 20, 2026 at 3:00 p.m. Pacific time. Shareholders may vote by internet, telephone, mail, or during the webcast using the 16-digit control number or QR code provided in proxy materials. How many Tandem (TNDM) shares were outstanding for voting purposes? There were 68,504,233 shares of Common Stock outstanding as of the Record Date, March 23, 2026, and each share is entitled to one vote on meeting matters. What change to the 2023 Long-Term Incentive Plan is being proposed? The board proposes to increase the number of shares authorized under the 2023 Plan by 3,260,000 shares and describes governance features like a minimum 12-month vesting rule and a director grant cap of $750,000 per fiscal year. What voting thresholds apply to the charter amendments in the proxy for TNDM? Approval of the Section 141(k) Amendment and the Officer Exculpation Amendment each requires the affirmative vote of holders of at least 66 2/3% of outstanding common shares on the Record Date. What financial highlights from 2025 does Tandem disclose in the proxy? The proxy cites more than $1.015 billion in worldwide sales for 2025, record Q4 sales above $290 million, and over 126,000 annual pump shipments, along with product rollouts and an FDA clearance of Control-IQ+ for type 2 diabetes.

Yahoo Finance
Mar 15th, 2026
Tandem Diabetes expands Mobi insulin pump to Android, aiming for $1.1B in 2026 sales

Tandem Diabetes Care has expanded its Tandem Mobi automated insulin delivery system to compatible Android smartphones in the US, following FDA clearance in November 2025 and a limited release in December. The Android rollout broadens accessibility for Mobi users and strengthens the company's position in smartphone-based diabetes management. The expansion supports Tandem's investment thesis by widening accessibility and reinforcing ecosystem retention, though near-term pressures remain from flat renewal expectations and ongoing losses. Combined with October 2025's integration of t:slim X2 with Abbott's FreeStyle Libre 3 Plus CGM, the move demonstrates a broader connectivity strategy. Tandem's narrative projects $1.2 billion revenue and $14.4 million earnings by 2028, requiring 7.5% yearly revenue growth. The company's 2026 sales guidance stands at approximately $1.065 billion to $1.085 billion.

Yahoo Finance
Mar 2nd, 2026
Tandem hits record 58% margin, plans pharmacy shift and tubeless 'Toby' pump launch

Tandem Diabetes Care reported a record fourth-quarter gross margin of 58%, driven by pricing, rising Mobi volume and early pharmacy channel adoption. The company is transitioning US sales to a pharmacy pay-as-you-go model, creating a near-term $70–$80 million revenue headwind in 2026 but offering materially higher long-term reimbursement—approximately double over four years and four times monthly versus durable medical equipment. Tandem is expanding direct international sales in Switzerland, Austria and the UK, with an expected average selling price uplift of at least 20%. The company plans to submit its tubeless Mobi cartridge, nicknamed "Toby", to the FDA in Q2 for commercial rollout in the second half of the year. The device will be compatible with existing Mobi pumps.

MarketScreener
Feb 25th, 2026
Tandem Diabetes Care prices upsized $265M convertible notes offering due 2032

Tandem Diabetes Care has priced a $265 million private placement of convertible senior notes due 2032, up from the initially announced $200 million. The notes carry a 0.00% interest rate and will mature on 15 March 2032. The insulin delivery and diabetes technology company estimates net proceeds of approximately $256.7 million after deducting fees and expenses. Initial purchasers have an option to buy an additional $35 million in notes. The notes will be convertible at an initial rate of 27.0362 shares per $1,000 principal amount, equivalent to a conversion price of approximately $36.99 per share. This represents a 37.5% premium over Tandem's closing stock price of $26.90 on 24 February 2026. Tandem plans to use proceeds for capped call transactions costing $13.5 million and general corporate purposes including potential acquisitions and working capital. The offering is expected to close on 27 February 2026.

Yahoo Finance
Feb 23rd, 2026
Brown Capital Management sells Tandem Diabetes as revenue growth disappoints, profitability goals missed

Brown Capital Management has sold its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM), citing weaker-than-expected performance, according to its fourth quarter 2025 investor letter. The San Diego-based diabetes technology company, which develops insulin pumps with advanced automated delivery systems, faced increasing competition and greater market saturation amongst Type 1 diabetes patients. Revenue growth fell short of expectations whilst the company remained unprofitable throughout 2025. Tandem reported worldwide sales of $290 million in Q4 2025, representing 15% year-over-year growth. The stock closed at $24.57 per share on 20 February 2026, down 24.77% over the previous 52 weeks. The company has a market capitalisation of $1.666 billion, with 33 hedge funds holding positions at the end of Q4.

INACTIVE